AB1010 (Pancreatic Cancer) - Analysis and Forecasts to 2020

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Introduction

2.1 Pancreatic Cancer
2.2 Pancreatic Cancer Market
2.3 Epidemiology
2.4 Etiology
2.5 The Main Recognized Risk Factors
2.5.1 Cigarette Smoking
2.5.2 Age
2.5.3 Gender
2.5.4 Family History
2.5.5 Other Factors
2.5.6 Pancreatic cancer prevention
2.6 GlobalData Report Guidance

3 Pancreatic Cancer: Market Characterization

3.1 Pancreatic Cancer Disease Market
3.2 Pancreatic Cancer Disease Market Forecasts and CAGR
3.3 Drivers for the Pancreatic Cancer Disease Market
3.3.1 High Incidence
3.3.2 Large Unmet Need
3.3.3 Active Pipeline

4 Tumor-Node-Metastases (TNM) Classification of Pancreatic Cancer

4.1 Treatment Options in Pancreatic cancer
4.2 Classification of Patients with Pancreatic Cancer

5 AB1010

5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Studies
5.4 Factors Affecting Sales of AB1010
5.4.1 Better Efficacy
5.4.2 Orphan Status in the EU
5.4.3 Future Competition
5.4.4 Commercialization Capabilities of the company
5.5 Drug Evaluation
5.5.1 Drug Risk Benefit Score
5.5.2 Intensity of Competition
5.6 Sales Estimates
5.6.1 Target Patient Pool of AB1010
5.6.2 Dosing
5.6.3 Market Penetration
5.6.4 Annual Cost of Therapy
5.6.5 Sales Forecasts of AB1010

6 Appendix

6.1 Market Definitions
6.2 Abbreviations
6.3 Research Methodology
6.3.1 Coverage
6.3.2 Secondary Research
6.3.3 Forecasting
6.3.4 Number of Patients Approved to Take the Drug
6.3.5 Net Penetration of Drug
6.3.6 Net Annual Dosing
6.3.7 Annual Cost of Therapy
6.4 Drug Sales Estimates Model
6.5 Contact Us
6.6 Disclaimer
6.7 Sources

List of Tables

Table 1: Pancreatic cancer, Estimated Incidence and Mortality, 2008–2030
Table 2: Pancreatic Cancer, TNM Classification
Table 3: AB1010, Pancreatic Cancer, Clinical Trial Results
Table 4: AB1010, Pancreatic Cancer, Drug Risk Benefit Score
Table 5: AB1010, Pancreatic Cancer, Global, Sales Forecasts ($m), 2013-2020
Table 6: AB1010, Pancreatic Cancer, The US, Sales Forecasts ($m), 2013-2020
Table 7: AB1010, Pancreatic Cancer, The UK, Sales Forecasts ($m), 2013-2020
Table 8: AB1010, Pancreatic Cancer, France, Sales Forecasts ($m), 2013-2020
Table 9: AB1010, Pancreatic Cancer, Germany, Sales Forecasts ($m), 2013-2020
Table 10: AB1010, Pancreatic Cancer, Italy, Sales Forecasts ($m), 2013-2020
Table 11: AB1010, Pancreatic Cancer, Spain, Sales Forecasts ($m), 2013-2020

List of Figures

Figure 1: Worldwide Incidence and Mortality Distribution of Top 20 Cancers (%), 2008
Figure 2: Total number of cigarettes consumed, The US, 1976-2006
Figure 3: Average Incidence Rate per 100,000, Pancreatic Cancer, the US, Both Sexes, 1992–2007
Figure 4: Incidence Rate per 100000, Pancreatic Cancer, the US, Both Sexes, 2010–2030
Figure 5: Pancreatic Cancer, Global, Market Size Forecasts ($m), 2010–2020
Figure 6: Pancreatic Cancer, Worldwide, Incidence (in million), 2008-2030
Figure 7: Oncology, Worldwide, Incidence (in million), 2008-2030
Figure 8: Broad Classification of Pancreatic Cancer
Figure 9: Classification of Patients with Pancreatic Cancer
Figure 10: AB1010, Pancreatic Cancer, Drug Model Diagram
Figure 11: AB1010, Pancreatic Cancer, Global, Sales Forecasts ($m), 2013-2020
Figure 12: AB1010, Pancreatic Cancer, The US, Sales Forecasts ($m), 2013-2020
Figure 13: AB1010, Pancreatic Cancer, The UK, Sales Forecasts ($m), 2013-2020
Figure 14: AB1010, Pancreatic Cancer, France, Sales Forecasts ($m), 2013-2020
Figure 15: AB1010, Pancreatic Cancer, Germany, Sales Forecasts ($m), 2013-2020
Figure 16: AB1010, Pancreatic Cancer, Italy, Sales Forecasts ($m), 2013-2020
Figure 17: AB1010, Pancreatic Cancer, Spain, Sales Forecasts ($m), 2013-2020
Figure 18: AB1010, Pancreatic Cancer, Global, Sales Distribution by Country (%), 2020
Figure 19: Patients Approved for the Drug 31